Concepedia

Benjamin L. Schlechter

BL

Statistics

Publications

27

Citations

1.1K

H-Index

19

Active since

1991

Affiliations

Dana-Farber Cancer Institute(Current)

Beth Israel Deaconess Medical Center

Harvard University

Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center

Benjamin L. Schlechter is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer immunotherapy.

Publications per year

1991–2024

27

Publications

27

Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer

Jeffrey I. Zwicker, Benjamin L. Schlechter, Jack D. Stopa et al. · JCI Insight · 2019 · 170 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium

Abhishek Jain, Andries D. van der Meer, Anne‐Laure Papa et al. · Biomedical Microdevices · 2016 · 142 citations · Full text

Engineering, Bioengineering, Biomedical Engineering +17

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih et al. · Nature Medicine · 2024 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17

CDKN1C/p57kip2is a candidate tumor suppressor gene in human breast cancer

Pamela S. Larson, Benjamin L. Schlechter, Chialin King et al. · BMC Cancer · 2008 · 58 citations · Full text

Medicine, Genetics, Oncology +17

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

Anthony B. El-Khoueiry, Marwan Fakih, Michael S. Gordon et al. · Journal of Clinical Oncology · 2023 · 55 citations

Medicine, Oncology, Pharmacology +17

1–5 of 27